Sage Therapeutics, Inc. (SAGE)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Total revenues | 31,660 | 11,871 | ||
| Selling, general and administrative | 61,997 | 53,219 | ||
| Restructuring | -230 | - | ||
| Research and development | 23,917 | 54,576 | ||
| Cost of revenues | -55 | 5,278 | ||
| Total operating costs and expenses | 85,629 | 113,073 | ||
| Loss from operations | -53,969 | -101,202 | ||
| Interest income | 4,323 | 7,642 | ||
| Other income (expense), net | -6 | 9 | ||
| Net loss | -49,652 | -93,551 | ||
| Unrealized gain (loss) on marketable securities | -127 | 1,592 | ||
| Total comprehensive loss | -49,779 | -91,959 | ||
| Net loss per share - basic | -0.79 | -1.53 | ||
| Net loss per share - diluted | -0.79 | -1.53 | ||
| Weighted average common stock outstanding - basic | 62,610,598 | 61,116,524 | ||
| Weighted average common stock outstanding - diluted | 62,610,598 | 61,116,524 | ||